Under a tenth of individuals eligible to benefit from GLP-1 drugs such as Wegovy can access them, caution the WHO as it issues its initial recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to this class of drugs.
Based on forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance acknowledges that obesity is a chronic disease that can be addressed with holistic and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key barriers to universal availability to the jabs that can aid individuals in losing substantial body mass, explains the organization.
Skinny Jab Shortage
Despite the present most favorable case, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of the global need, per the WHO.
The advice encourages governments and firms to expand access, by approaches such as patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Weight-Loss Jabs Work
These medications replicate a natural hormone to slow digestion, suppress the appetite and boost satiety so individuals consume fewer calories.
Individuals commonly begin shedding pounds within a few weeks of beginning the regular doses.
Studies indicates patients may see weight return a year later of stopping the treatment, because their normal appetite return.
Being carrying excess weight elevates your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
